Folinic Acid as a Treatment for Autism Spectrum Disorder in Children (FOLIN-A)
Folinic Acid as a Treatment for Autism Spectrum Disorder in Children: A Double-blind Randomised Placebo-controlled Trial With Open Label Extension (FOLIN-A Trial)
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Study Coordinator
- Telefonnummer: 6563947201
- E-mail: folin-a@kkh.com.sg
Studiesteder
-
-
Singapore
-
Singapore, Singapore, Singapore
- Rekruttering
- KK Women's and Children's Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Children aged 3 years 0 months to 10 years 11 months at the time of enrolment
- Weight ≥ 10 kg and ≤ 30 kg at the time of enrolment
- Confirmed diagnosis of Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) or Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria, supported by standardized diagnostic assessments
- Stable on regular behavioral interventions and any medications for at least 6 months prior to enrolment
- At least one parent or legal guardian able to understand and complete study questionnaires in English
- Written informed consent obtained from a parent or legal guardian
Exclusion Criteria:
- Known allergy or intolerance to folinic acid
- Current or prior supplementation with folinic acid or other folate preparations (folic acid supplementation permitted)
- Vitamin B12 (cobalamin) deficiency or pernicious anemia
- Concurrent use of medications known to interfere with folate metabolism (e.g., methotrexate, trimethoprim, fluorouracil, capecitabine, glucarpidase)
- Known genetic, metabolic, or chromosomal disorder, or structural brain abnormalities
- History of epilepsy or seizures (except simple febrile seizures) or current use of antiepileptic or antipsychotic medication
- Significant sensory (hearing or visual) or motor impairment
- Participation in another interventional clinical trial for autism within the past 6 months
- Unable or unwilling to comply with study visits and procedures
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Folinic Acid
Participants in this arm will receive folinic acid during the double-blind randomised controlled trial (RCT) phase of the study.
After completion of the double-blind phase, participants will continue into an open-label extension in which folinic acid is provided.
|
Oral folinic acid administered during the double-blind randomised controlled trial (RCT) phase, followed by open-label folinic acid treatment.
|
|
Placebo komparator: Placebo
Participants in this arm will receive a matching placebo during the double-blind randomised controlled trial (RCT) phase of the study.
After completion of the double-blind phase, participants will continue into an open-label extension in which folinic acid is provided.
|
Matching oral placebo administered during the double-blind randomised controlled trial (RCT) phase.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Pervasive Developmental Disorder-Behavior Inventory (PDDBI) Autism Composite T-Score
Tidsramme: Baseline to Week 12
|
The Pervasive Developmental Disorder-Behavior Inventory (PDDBI) is a validated caregiver-completed instrument used to assess adaptive and maladaptive behaviors in individuals with autism spectrum disorder (ASD).
The Autism Composite T-score is a standardized score (mean = 50, standard deviation = 10) that summarizes overall autism symptom severity, with higher scores indicating greater symptom severity.
This outcome measure evaluates the change from baseline to Week 12 in PDDBI Autism Composite T-score.
Lower T-scores indicate improvement in autism-related symptoms.
Changes in scores will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in language function as measured by the Clinical Evaluation of Language Fundamentals (CELF)
Tidsramme: Baseline to Week 12
|
Change from baseline to Week 12 in standardized language function scores as assessed using the Clinical Evaluation of Language Fundamentals (CELF), a standardized individually administered assessment of receptive and expressive language skills in children.
CELF standardized scores have a mean of 100 and a standard deviation of 15, with higher scores indicating better language performance.
Changes in scores will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
|
Change from baseline in receptive vocabulary score as measured by the Receptive One-Word Picture Vocabulary Test (ROWPVT)
Tidsramme: Baseline to Week 12
|
Change from baseline to Week 12 in standardized receptive vocabulary scores as assessed using the Receptive One-Word Picture Vocabulary Test (ROWPVT), a standardized individually administered assessment of a child's ability to understand spoken words.
Scores are standardized with a mean of 100 and a standard deviation of 15, where higher scores indicate better receptive vocabulary ability.
Changes in scores will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
|
Change from baseline in expressive vocabulary score as measured by the Expressive One-Word Picture Vocabulary Test (EOWPVT)
Tidsramme: Baseline to Week 12
|
Change from baseline to Week 12 in standardized expressive vocabulary scores as assessed using the Expressive One-Word Picture Vocabulary Test (EOWPVT), a standardized individually administered assessment of a child's ability to produce spoken words.
Scores are standardized with a mean of 100 and a standard deviation of 15, where higher scores indicate better expressive vocabulary ability.
Changes in scores will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
|
Change from baseline in Clinical Global Impression-Severity and Improvement scores as measured by the Clinical Global Impression Scale (CGI-S and CGI-I)
Tidsramme: Baseline to Week 12
|
Change from baseline to Week 12 in Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scores, assessed using the Clinical Global Impression Scale, a standardized assessor-rated measure of illness severity and overall clinical improvement.
CGI-S scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill), where lower scores indicate better outcomes, and CGI-I scores range from 1 (very much improved) to 7 (very much worse), where lower scores indicate greater improvement.
Changes in scores will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
|
Change from baseline in Aberrant Behavior Checklist total score as measured by the Aberrant Behavior Checklist (ABC)
Tidsramme: Baseline to Week 12
|
Change from baseline to Week 12 in total scores on the Aberrant Behavior Checklist (ABC), a standardized caregiver-completed questionnaire that assesses behavioural symptoms in children across domains such as irritability, lethargy, stereotypy, hyperactivity, and inappropriate speech.
Total scores range from 0 to 174, with higher scores indicating greater severity of behavioural problems (worse outcomes).
Changes in scores will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
|
Change from baseline in total problem score as measured by the Child Behavior Checklist (CBCL)
Tidsramme: Baseline to Week 12
|
Change from baseline to Week 12 in total problem scores on the Child Behavior Checklist (CBCL), a standardized caregiver-reported questionnaire that assesses a broad range of emotional and behavioural problems in children.
Total scores are standardised T-scores (typically ranging from approximately 30 to 100, with a mean of 50 and standard deviation of 10), where higher scores indicate greater behavioural and emotional problems (worse outcomes).
Changes in scores will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
|
Change from baseline in adaptive behavior composite score as measured by the Vineland Adaptive Behavior Scales (VABS)
Tidsramme: Baseline to Week 12
|
Change from baseline to Week 12 in standardised adaptive behavior scores as assessed using the Vineland Adaptive Behavior Scales (VABS), a standardized caregiver-reported assessment of a child's adaptive functioning across domains such as communication, daily living skills, socialization, and motor skills.
Adaptive behavior composite scores are standardised (typically ranging from approximately 20 to 160, with a mean of 100 and standard deviation of 15), where higher scores indicate better adaptive functioning (better outcomes).
Changes in scores will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
|
Change from baseline in proportion of gaze duration to social stimuli as measured by eye-tracking assessment
Tidsramme: Baseline to Week 12
|
Change from baseline to Week 12 in eye-tracking measures of visual attention, specifically the proportion of total gaze duration directed toward social stimuli (e.g., faces or biological motion) compared with non-social stimuli, assessed using a standardized eye-tracking paradigm.
Higher proportions indicate greater relative attention to social stimuli.
Changes in proportions will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
|
Incidence of adverse events and serious adverse events as measures of safety and tolerability of folinic acid
Tidsramme: Baseline to Week 24
|
Change from baseline to Week 24 in the incidence of adverse events (AEs) and serious adverse events (SAEs), monitored throughout the study period to assess the safety and tolerability of folinic acid treatment.
|
Baseline to Week 24
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in plasma glutathione redox ratio (GSH:GSSG)
Tidsramme: Baseline to Week 12
|
Change from baseline to Week 12 in plasma glutathione redox ratio (reduced glutathione:oxidized glutathione; GSH:GSSG), a biomarker of oxidative stress balance.
Higher ratios indicate a more reduced (favorable) redox state.
Plasma reduced glutathione (GSH, µM) and oxidized glutathione (GSSG, µM) will be measured at baseline (T1) and Week 12 (T2).
|
Baseline to Week 12
|
|
Change from baseline in plasma methylation ratio (S-adenosylmethionine:S-adenosylhomocysteine; SAM:SAH)
Tidsramme: Baseline to Week 12
|
Change from baseline to Week 12 in plasma methylation ratio (S-adenosylmethionine:S-adenosylhomocysteine; SAM:SAH), a biomarker of methylation capacity.
Higher ratios indicate greater methylation potential (better outcomes).
Additional biomarkers related to one-carbon metabolism, including plasma homocysteine (µmol/L), will measured where available.
|
Baseline to Week 12
|
|
Change in Plasma Ergothioneine Levels
Tidsramme: Baseline to Week 12
|
Change from baseline to Week 12 in plasma ergothioneine concentration (ET, nM).
Plasma ergothioneine (ET, nM), hercynine (nM), and ophthalmic acid will be measured at baseline (T1) and Week 12 (T2).
|
Baseline to Week 12
|
|
Change in Folate Status Biomarkers
Tidsramme: Baseline to Week 12
|
Change from baseline in serum and plasma folate status biomarkers.
Folate status biomarkers include measures related to one-carbon metabolism and amino acid pathways.
Plasma amino acid concentrations (µmol/L) will be interpreted with reference to established age-specific clinical ranges.
|
Baseline to Week 12
|
|
Association of FRAA Status With Treatment Response
Tidsramme: Baseline to Week 12
|
Association between folate receptor autoantibody (FRAA) status and change in autism outcome measures.
FRAA status will be classified as positive or negative based on the assay-specific cutoff defined by the testing laboratory: Blocking FRAA (pmol blocked per mL) and binding FRAA (optical density [OD] units per µL).
|
Baseline to Week 12
|
|
Sustained Effects of Folinic Acid on Autism Symptoms
Tidsramme: Baseline to Week 24
|
Change from baseline in autism outcome measures following 24 weeks of folinic acid treatment.
|
Baseline to Week 24
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Psykiske lidelser
- Neuroudviklingsforstyrrelser
- Børns udviklingsforstyrrelser, gennemgående
- Autismespektrumforstyrrelse
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Enzymer og coenzymer
- Formyltetrahydrofolater
- Tetrahydrofolater
- Folinsyre
- Pterins
- Pteridiner
- Coenzymer
- Leucovorin
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- FOLIN-A-01
- MOH-CIRG24jan-0004 (Andet bevillings-/finansieringsnummer: National Medical Research Council (NMRC), Singapore)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .